Discovery of 17 Gliptins in 17-Years of Research for the Treatment of Type 2 Diabetes: A Synthetic Overview
IR@CDRI: CSIR-Central Drug Research Institute, Lucknow
View Archive Info| Field | Value | |
| Creator |
Kushwaha, R N
Haq, W Katti, S B |
|
| Date |
2014-09-19T07:57:09Z
2014-09-19T07:57:09Z 2014 |
|
| Identifier |
Chemistry & Biology Interface, 2014, 4(3), 137-162
http://hdl.handle.net/123456789/1409 |
|
| Description |
Gliptins, commonly known as clinical DPP-IV inhibitors have become a new class of potential drug candidate and are being hoped as a permanent eraser for type 2 diabetes. Therefore, gliptins have been a centre of research and development. As a result of the efforts made towards developing effective gliptins, the first clinical proof of concept for efficacy was confirmed in 1998 when NVP-DPP728 came into focus. Thus, from 1998 to 2014, these 17-years of the heightened research towards drug discovery has resulted in seventeen gliptins. Among these, eight gliptins are currently approved and in clinical usages for type 2 diabetes therapies, while others are in different stages of clinical trials. This review covers the various approaches and methodologies used in the syntheses of only those DPP-IV inhibitors in clinical uses having suffix gliptin. In addition, it also encompasses their biological activity and their binding interactions in the active site of DPP-IV that are responsible for their drug candidacy.
|
|
| Format |
724148 bytes
application/pdf |
|
| Language |
en
|
|
| Relation |
CSIR-CDRI Communication No. 8713
|
|
| Subject |
Discovery
Gliptins 17-Years of Research for the Treatment Type 2 Diabetes Ynthetic Overview |
|
| Title |
Discovery of 17 Gliptins in 17-Years of Research for the Treatment of Type 2 Diabetes: A Synthetic Overview
|
|
| Type |
Article
|
|